Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Copanlisib

Copanlisib vials 60 mg

DRUG

R-CHOP Chemotherapy

Immunochemotherapy

Trial Locations (12)

28205

Klinikum-Bremen-Mitte, Bremen

44137

St.-Johannes-Hospital Dortmund, Dortmund

48149

University Hospital Muenster, Münster

52074

University Hospital RWTH Aachen, Aachen

67655

Westpfalz-Klinikum, Kaiserslautern

70174

Hospital Stuttgart - Stuttgart Cancer Center, Stuttgart

81377

Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich

84036

ÜBAG MVZ Dr. Vehling-Kaiser GmbH, Landshut

89081

University Hospital Ulm, Ulm

01127

Onkozentrum Dresden, Dresden

06120

University Hospital Halle, Halle

04103

University Hospital Leipzig, Leipzig

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Hospital Muenster

OTHER